Quick Answer
RenovoRx, Inc. reported R&D Expense of $6.27 million for fiscal year 2025.
RenovoRx, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.27M | +4.0% |
| 2024 | $6.03M | +6.3% |
| 2023 | $5.67M | +31.8% |
| 2022 | $4.30M | +41.5% |
| 2021 | $3.04M | +27.4% |
| 2020 | $2.39M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.69M | +2.1% | +18.2% |
| June 30, 2025 | $1.43M | -7.5% | -13.2% |
| March 31, 2025 | $1.64M | +30.6% | -0.5% |
| September 30, 2024 | $1.65M | +1.3% | +7.0% |
| June 30, 2024 | $1.54M | -19.9% | +22.7% |
| March 31, 2024 | $1.26M | -6.1% | -22.8% |
| September 30, 2023 | $1.63M | +92.6% | -15.4% |
| June 30, 2023 | $1.93M | +38.5% | +43.9% |
- RenovoRx, Inc. showed an increase of +4.0% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, RenovoRx, Inc.’s r&d expense has grown by 162.7% (from $2.39 million to $6.27 million).
- The most recent figure is from RenovoRx, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: